1,379 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
zg0895 hydrochloride for Cancer	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P1	C (36)
Zirconium Zr 89-Dfo-Ys5 Cancer	Robert Flavell, MD, PhD	P1	C (36)
zw191 Cancer	Zymeworks BC Inc.	P1	C (36)
zx-4081 Cancer	Nanjing Zenshine Pharmaceuticals	P1	C (36)
zx-8177 Cancer	Nanjing Zenshine Pharmaceuticals	P1	C (36)
Γδ T-Pd-1 Ab Cells Cancer	Changzhou No.2 People's Hospital	P1	C (36)
bi 1701963 Cancer	Mirati Therapeutics Inc.	P1	C (35)
m9466 Cancer	EMD Serono Research & Development Institute, Inc.	P1	C (34)
Milademetan Cancer	Rain Oncology Inc	P1/2	C (34)
rd133 Cancer	Tongji Hospital	Early P1	C (34)
177lu-rad202 Cancer	Radiopharm Theranostics, Ltd	Early P1	C (33)
[68Ga]Ga-R54 Cancer	National Cancer Institute, Naples	Early P1	C (33)
Amt-676 Cancer	Multitude Therapeutics Inc.	Early P1	C (33)
Anti-Car-Nk Cells Cancer	Wuxi People's Hospital	Early P1	C (33)
b7h3 car-γδt cells Cancer	Peking University	Early P1	C (33)
Biological: Innopcv Cancer	The Affiliated Hospital Of Guizhou Medical University	Early P1	C (33)
Car-Dc Cancer	Peking University Shenzhen Hospital	Early P1	C (33)
Debio 0123 Cancer	Debiopharm International SA	P1	C (33)
gc203 til Cancer	Shanghai Juncell Therapeutics	Early P1	C (33)
Hs-It101 Cancer	The Affiliated Hospital of Qingdao University	Early P1	C (33)
ibr900 cell Cancer	Beijing Boren Hospital	Early P1	C (33)
im92 car-t cells Cancer	Beijing Immunochina Medical Science & Technology Co., Ltd.	Early P1	C (33)
im96 car-t cells Cancer	Beijing Immunochina Medical Science & Technology Co., Ltd.	Early P1	C (33)
kt095 car-t Cancer	The First People's Hospital of Lianyungang	Early P1	C (33)
mb1707 Cancer	Mainline Biosciences, Inc.	Early P1	C (33)
Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-Til) Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Early P1	C (33)
mpt0b640 Cancer	J Ints Bio	Early P1	C (33)
nk521 cell Cancer	Base Therapeutics (Shanghai) Co., Ltd.	Early P1	C (33)
Personalized Neoantigen Tumor Vaccine Cancer	Ruijin Hospital	Early P1	C (33)
Saprna™-Mica/B Tumor Vaccine Cancer	NING LI	Early P1	C (33)
TIL Cancer	Shanghai Juncell Therapeutics	Early P1	C (33)
[18f]f-resca-g5 Cancer	RenJi Hospital	N/A	D (30)
[18f]f-resca-rb14 Cancer	RenJi Hospital	N/A	D (30)
[18F]F-RESCA-RND20 Cancer	RenJi Hospital	N/A	D (30)
[18F]F-RESCA-T4 Cancer	RenJi Hospital	N/A	D (30)
[18f]f-resca-wwh347 Cancer	RenJi Hospital	N/A	D (30)
[68Ga]Ga-DOTA-H2D3 Cancer	RenJi Hospital	N/A	D (30)
[68ga]ga-nota-g5 Cancer	RenJi Hospital	N/A	D (30)
[68ga]ga-nota-rnd20 Cancer	RenJi Hospital	N/A	D (30)
[68ga]ga-nota-t4 Cancer	RenJi Hospital	N/A	D (30)
[68Ga]Ga-NOTA-WWH347 Cancer	RenJi Hospital	N/A	D (30)
68ga-psma Cancer	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	N/A	D (30)
Bemotuzumab Cancer	Zhejiang Provincial People's Hospital	N/A	D (30)
Jojoba Oil Cancer	City of Hope Medical Center	N/A	D (30)

Showing 1251 to 1300 of 1,379 assets

PreviousPage 26 of 28Next